Visit the Regional Educational Programs for more information about the following upcoming programming:

Member Institution Programs:

Industry Supported Programs:

Nonprofit Sponsored Programs:

• September 2025 - March 2026 - American Cancer Society's Building Pathways to Fertility Preservation in Cancer (monthly virtual sessions)

Welcome, new board fellow liaisons!

Join us in thanking our outgoing fellow liaisons & wishing them the best of luck in their future endeavors!

https://asco.quorum.us/campaign/56411/

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Latest FDA Approval

• September 25 - FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
• September 19 - FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection
• September 11 - FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
• September 9 - FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
• August 8 - FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
• August 6 - FDA grants accelerated approval to dordaviprone for diffuse midline glioma
• July 2 - FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma
• July 2 - FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
• June 23 - FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer
  June 18 - FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
• June 12 - FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
• June 12 - FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
• June 11 - FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
• June 3 - FDA approves darolutamide for metastatic castration-sensitive prostate cancer
• May 14 - FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
• May 14 - FDA approves belzutifan for pheochromocytoma or paraganglioma
• May 8 - FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

Package/Label Updates

Code Updates

• Claim Issue Reported 1/8/25 impacting Part B providers in Jurisdiction JK and Jurisdiction J6 - Claims with healthcare common procedure coding system (HCPCS) G2211 with date of service (DOS) 1/1/2024-9/30/2024.

• Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
  

Other Updates